Clinical trial · Observational
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Real-world Treatment Patterns and Clinical Outcomes in Epidermal Growth Factor Receptor(EGFR)-Mutant Unresectable Locally Advanced NSCLC: A Retrospective Multi-center Study
NCT04304638CI-TRIAL-00043961unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EGFR Mutation-Related Tumors | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Stage III Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EGFR-TKI Inhibitor | Drug | — | UNRESOLVED |
| radiation or chemo-radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Radiation(Chemo-radiation)
- description
- Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.
- interventionNames
- Radiation: radiation or chemo-radiation
- label
- radiation+EGFR-TKI
- description
- Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.
- interventionNames
- Radiation: radiation or chemo-radiation
- Drug: EGFR-TKI Inhibitor
- label
- EGFR-TKI
- description
- Patients in this group had been treated with EGFR-TKI without any other treatment until progression.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed NSCLC with adenocarcinoma * stage III (AJCC 7th edition) * inoperable or refuse surgery * EGFR-TKI mutation, specimen from tissue or blood Exclusion Criteria: * the pathology was not adenocarcinoma * stage I,II and IV * anaplastic lymphoma kinase (ALK) rearrangement * no follow-up data achievable
References
Publications (0)
Data not yet available
No reference posted for this study.